Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 8/20 | 0.74 |
| ▸ | DDB1 | Q16531 | 4/20 | 0.74 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | PYGL | P06737 | 2/20 | 0.49 |
| ▸ | PYGM | P11217 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19370841 | 0.85 | CRBN (1.00) | CRBNDDB1IKZF3ALDH1A1PYGL | |
| SCHEMBL20773238 | 0.85 | CRBN (1.00) | CRBNDDB1IKZF3ALDH1A1PYGL | |
| SCHEMBL5742534 | 0.85 | CRBN (1.00) | CRBNDDB1IKZF3ALDH1A1PYGL | |
| SCHEMBL25834128 | 0.82 | DDB1 (0.51) | CRBNDDB1ALDH1A1RAB9ANPC1 | |
| SCHEMBL25834384 | 0.81 | CRBN (0.77) | CRBNDDB1IKZF3ALDH1A1 | |
| SCHEMBL26500910 | 0.80 | CRBN (0.77) | CRBNDDB1IKZF3ALDH1A1PYGL | |
| SCHEMBL25834372 | 0.79 | ALDH1A1 (0.51) | CRBNDDB1IKZF3ALDH1A1RAB9A | |
| SCHEMBL27053430 | 0.78 | CRBN (0.52) | CRBNDDB1IKZF3ALDH1A1PYGL | |
| SCHEMBL11903535 | 0.77 | DDB1 (0.65) | CRBNDDB1IKZF3ALDH1A1HTT | |
| SCHEMBL20128673 | 0.77 | CRBN (0.55) | CRBNDDB1IKZF3PYGLPYGM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230226035-A1 | SMALL MOLECULES AGAINST CEREBLON TO ENHANCE EFFECTOR T CELL FUNCTION | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230226035-A1 | SMALL MOLECULES AGAINST CEREBLON TO ENHANCE EFFECTOR T CELL FUNCTION | CD4, CRBN, GZMB | CRBN 2/4885DDB1 3336/4885IKZF3 274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.